IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome

Clinical trial NCT03175978 · TERMINATED

Trial details

NCT number: NCT03175978
Sponsor: IGF Oncology, LLC
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic Anemia, Refractory, With Excess of Blasts

Start date: 2018-02-21
Primary completion: 2021-06-30
Enrollment: 2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.